Yeast Infection Treatment Market Report 2026

Yeast Infection Treatment Market Overview

• Yeast Infection Treatment market size has reached to $4.62 billion in 2025 • Expected to grow to $6.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Autoimmune Disease Surge Fuels Growth In Yeast Infection Treatment Market • Market Trend: adoption Of Next Generation Treatments For Improved Infection Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Yeast Infection Treatment Market?

Yeast infection treatment is a medication employed to address and resolve infections caused by the overgrowth of the Candida fungus, commonly known as a yeast infection. These infections, known as candidiasis or yeast infections, can occur in various parts of the body, including the mouth (oral thrush), genitals (vaginal yeast infection), skin, and other mucous. They are used to relieve the symptoms of a yeast infection. The main types of yeast infection treatment are powders, creams or ointments, tablets or capsules, and others. Various types of treatments include medical treatment and surgery. Several types of indications are included, such as genital candidiasis, invasive candidiasis, oropharyngeal or esophageal candidiasis (thrush), and others. It can be administered through various routes, including oral, topical, IV (intravenous) or IM (intramuscular), and others, and is used in several applications, such as retail pharmacies or drug stores, hospital pharmacies, specialty stores, online sales, and others.

What Is The Yeast Infection Treatment Market Growth Forecast?

The yeast infection treatment market size is expected to see strong growth in the next few years. It will grow to $6.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing focus on resistant candida strains, rising demand for long-term management solutions, expansion of online pharmacy channels, growing development of novel antifungal agents, increasing emphasis on patient-centric treatment approaches. Major trends in the forecast period include increasing adoption of combination antifungal therapies, growing demand for over-the-counter treatment options, expansion of probiotic-based adjunct therapies, rising focus on recurrence prevention strategies, improved patient awareness and diagnosis.

What Is The Driver Of The Yeast Infection Treatment Market?

The rise in the prevalence of autoimmune disease is expected to propel the growth of the yeast infection treatment market going forward. Autoimmune disease is a condition where the immune system mistakenly attacks healthy cells, tissues, and organs, weakening bodily function and potentially becoming life-threatening. Yeast infection treatment are used in managing and preventing the complications of autoimmune disease by addressing recurrent yeast infections, which are linked to certain autoimmune syndromes, and by potentially modulating the immune response through the management of fungal infections in patients with autoimmune conditions. For instance, in November 2023, according to the Multiple Sclerosis International Federation (MSIF), a UK-based international nonprofit organization focused on global MS research and advocacy, an estimated 2.9 million people worldwide were living with multiple sclerosis, a type of autoimmune disease in 2023. Therefore, the rise in the prevalence of autoimmune diseases is driving the growth of the yeast infection treatment industry.

Key Players In The Global Yeast Infection Treatment Market

Major companies operating in the yeast infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Abbott Laboratories, AstraZeneca PLC, Bayer AG, Astellas Pharma Inc., Torrent Pharmaceuticals, Cipla, Glenmark Pharmaceuticals Ltd, Zydus Lifesciences, Brundavan Laboratories Private Limited, Prestige Consumer Healthcare Inc., Synmedic Laboratories, Basilea Pharmaceutica AG, Jubilant Pharmova Limited, Johnson & Johnson, GlaxoSmithKline plc, Gilead Sciences Inc., SCYNEXIS Inc., Leadiant Biosciences Inc.

Global Yeast Infection Treatment Market Trends and Insights

Major companies operating in the yeast infection treatment market are focusing on incorporating next generation antifungal therapies as an advanced pharmaceutical innovation to enhance treatment effectiveness, patient outcomes, and long-term recurrence control. Advanced antifungal therapies are medications designed to target specific fungal mechanisms such as enzyme inhibition more selectively and more potently than older broad-spectrum drugs, enabling capabilities such as higher cure rates, reduced recurrence, and fewer side effects. For instance, in February 2024, Mycovia Pharmaceuticals Inc, a US based biopharmaceutical company, together with Jiangsu Hengrui Pharmaceuticals Co Ltd, a China based pharmaceutical company specializing in innovative drug research and commercialization, launched VIVJOA oteseconazole capsules, a next generation oral antifungal designed to treat severe vulvovaginal candidiasis. VIVJOA features a short two-day oral course, selective inhibition of the fungal CYP51 enzyme which minimizes impact on human enzymes, and improved cure and mycological cure rates compared with fluconazole. VIVJOA enhances treatment effectiveness, enables rapid symptom relief, and reduces the likelihood of recurrence, thereby strengthening the value proposition of prescription grade yeast infection therapies.

What Are Latest Mergers And Acquisitions In The Yeast Infection Treatment Market?

In March 2023, GlaxoSmithKline Plc, a UK-based biopharma company, partnered with Scynexis to develop Brexafemme (isavuconazonium sulfate) for the treatment of vaginal yeast infections. As a result of the partnership, the availability and accessibility of this innovative treatment will be significantly enhanced. This is especially beneficial for patients dealing with difficult infections caused by resistant fungi. Scynexis is a US-based biotechnology company specializing in developing innovative therapies for difficult-to-treat infections, particularly fungal infections.

What Defines the Yeast Infection Treatment Market?

The yeast infection treatment market consists of revenues earned by entities by providing diagnostic testing, personalized treatment plans, telemedicine consultations, educational programs and more. The market value includes the value of related goods sold by the service provider or included within the service offering. The yeast infection treatment market also includes sales of miconazole, terconazole, fluconazole, amphotericin B, itraconazole, and caspofungin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Yeast Infection Treatment Market Report 2026?

The yeast infection treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the yeast infection treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.